---
title: "Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260282428.md"
description: "According to TipRanks, Brayer is a 3-star analyst with an average return of 4.4% and a 40.98% success rate. Brayer covers the Healthcare sector, focusing on stocks such as United Therapeutics, BioMarin Pharmaceutical, and Alnylam Pharma. Currently, the analyst consensus on Verona Pharma is a Hold with an average price target of $106.22."
datetime: "2025-10-08T12:16:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260282428.md)
  - [en](https://longbridge.com/en/news/260282428.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260282428.md)
---

# Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)

According to TipRanks, Brayer is a 3-star analyst with an average return of 4.4% and a 40.98% success rate. Brayer covers the Healthcare sector, focusing on stocks such as United Therapeutics, BioMarin Pharmaceutical, and Alnylam Pharma.

Currently, the analyst consensus on Verona Pharma is a Hold with an average price target of $106.22.

### Related Stocks

- [VRNA.US](https://longbridge.com/en/quote/VRNA.US.md)

## Related News & Research

- [FACTBOX-IPO-bound SpaceX's board is stacked with Musk empire loyalists](https://longbridge.com/en/news/287206089.md)
- [INSTANT VIEW-SpaceX files long awaited IPO, creating a fresh AI play](https://longbridge.com/en/news/287124128.md)
- [ANALYSIS-Why SpaceX's mega IPO may not signal a broader rebound in listings](https://longbridge.com/en/news/287215490.md)
- [GRAPHIC-Major takeaways from Magnificent Seven's AI-fueled earnings](https://longbridge.com/en/news/287224928.md)
- [Walmart CFO Warns Higher Prices Could Hit Shelves In Coming Months](https://longbridge.com/en/news/287231542.md)